Company / Net Debt per Share
Edwards Lifesciences Net Debt per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$4.03
FY2025
5-year range
-$4.07 / -$0.28
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
#88 of 98
Health Care
What the data says
Among 98 Health Care companies, Edwards Lifesciences is in the top 10% for net debt per share. Net Debt per Share returned to growth in FY2025 after 2 years of decline, reaching $-4.03.
Based on SEC 10-K filings.
-4.03 in FY2025.
Improved from $-0.90 to $-4.03 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 98This company -$4.03 Sector average $7.39
▼
-154.5% below sector average
Key checks
Key Insights
- In FY2025, net debt per share increased 1.0% year-over-year.
- Ranks #88 out of 98 companies in the Health Care sector.
- Peak net debt per share was recorded in FY2022.
- Lowest net debt per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.03 | +1.0% |
| FY2024 | -$4.07 | -352.8% |
| FY2023 | -$0.90 | -216.7% |
| FY2022 | -$0.28 | +33.7% |
| FY2021 | -$0.43 | +54.6% |
| FY2020 | -$0.94 | +66.3% |
| FY2019 | -$2.80 | -382.8% |
| FY2018 | -$0.58 | +67.7% |
| FY2017 | -$1.80 | -252.4% |
| FY2016 | -$0.51 | +54.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026